Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of ...

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does ...

Also Read: Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study The study involved patients aged 25 to 55 who were infected with SARS-CoV ...

There is no proven treatment for long Covid-19, which can cause a range of debilitating symptoms in millions of Americans. Skip to content. Exclusive ...

U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.

Pfizer will provide up to 6 million courses of its antiviral COVID-19 treatment, Paxlovid, for the Global Fund, the pharmaceutical company said Sept. 22.

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to a lower rate of COVID-19 infections in the U.S. and a drop in purchases by governments.